Human milk oligosaccharides (HMOs) have been paid much attention due to their beneficial effects observed in vitro, e.g., prebiotic, anti-infective and anti-inflammatory properties. However, in vivo investigations with regard to HMO metabolism and functions are rare. The few data available indicate that HMOs are absorbed to a low extent and excreted via urine without noteworthy modifications, whereas the major proportion reaches infant's colon undigested. Via intrinsic 13 C-labeling of HMOs during their biosynthesis in the mammary gland of 10 lactating women, we were able to follow the fate of 13 C-labeled oligosaccharides (OSs) from their secretion in milk to the excretion in the urine of their breastfed infants. To a certain extent, we could therefore discriminate between original HMOs and non-labeled OSs derived from degradation of HMOs or endogenous glycoconjugates. By means of our novel, rapid, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based approach, we found a homogeneous time pattern of isotopomer enrichment in milk among all subjects and between single OS species. In contrast, the time curves from infants' urine varied strongly between individuals and OS species, though the overall MALDI-TOF MS profile resembled those of the mothers' milk. Our data suggest that neutral HMOs might be processed and/or utilized differentially after or upon absorption from the gut, as deduced from their structure-dependent variation in the extent of tracer enrichment and in the retention times in infant's organism. This sheds new light on the role of HMOs within infant's body, beyond the intestine and its microbiota alone.
Introduction
It is well known that breastfed infants have various health benefits compared with formula-fed babies, e.g. less-frequent autoimmune diseases and fewer or less severe infections of the respiratory, intestinal and uro-genital tract (Pisacane et al. 1992; Schack-Nielsen and Michaelsen 2007) . In this regard, human milk oligosaccharides (HMOs) are supposed to contribute to these beneficial outcomes through their prebiotic, anti-infective and immunomodulatory effects, as revealed from numerous in vitro and few animal and human observational studies Bode 2012 ). Since HMOs are products of the action of different glycosyltransferases in the mammary gland and, therefore, evolve large structural variety, it is not surprising that their efficacy and absorption have been found to be dependent on the individual structures (Gnoth et al. 2001; Bode 2012) , including specific sites of fucosylation (Morrow et al. 2011) or sialylation (Bode et al. 2004) . Lactose as the backbone of HMOs can be elongated with N-acetylglucosamine (GlcNAc) and galactose (Gal) residues to form GlcNAcβ1-3Gal or GlcNAcβ1-4Gal units, the former resulting in the main core structure, lacto-N-tetraose (LNT), the latter in neo-LNT or LNnT. These structures can be further elongated and branched, or also modified by the attachment of α1-2-/α1-3-or α1-4-linked fucose and/or N-acetylneuraminic acid, the latter forming acidic HMOs (Kobata 2010) .
Although oligosaccharides (OSs) are the third largest component of human milk with concentrations ranging from 5 to 20 g/ L (Thurl et al. 2010; Coppa et al. 2011) , their metabolism and functions in vivo are poorly understood. This is partly due to several practical and analytical limitations. In previous studies with and without the use of stable isotopes, we found a renal excretion of 1-3% of individual HMOs in exclusively breastfed infants (Rudloff et al. 1996 . Over the last years, various state-of-the-art methodologies have emerged enabling a sophisticated identification of the majority of the >200 distinct OS structures found in human milk, infant feces and urine. These techniques include chromatography (Chaturvedi et al. 2001; , capillary electrophoresis (Shen et al. 2000; Albrecht et al. 2011) , mass spectrometry (Klein et al. 1998; Kogelberg et al. 2004 ) as well as on-line coupled combinations of those (Galeotti et al. 2012; De Leoz et al. 2013 ).
Practical constraints of clinical studies on HMOs include their limited availability and affordability for the use in humans . Ethical considerations are also impeding the much-needed functional studies, since infants as well as lactating women are particularly vulnerable subpopulations. Consequently, study design and sampling procedures should be of minimal discomfort and risks for mother and child. Therefore, we used intrinsic stable isotope labeling as an established and straightforward, noninvasive technique (Davidsson and Tanumihardjo 2011) .
Breastfeeding women ingested 13 C-Gal, which was incorporated into HMOs during their synthesis in the mammary gland. Subsequently, we were able to track the stable isotope tracer over the course of time including its renal excretion in the breastfed child by measuring 13 C-enrichment in whole or fractionated mother's milk and infants' urine by means of isotope ratio MS (IRMS) (Rudloff et al. 2006 . Although IRMS is very sensitive in the determination of isotope enrichment, it does not distinguish between single compounds, unless they were isolated prior to analysis in a tedious procedure requiring large sample volumes, in particular, in case of urinary OSs. Hence, we have developed a rapid matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based approach (see also Blank et al. 2011) for the determination of isotopomer enrichment in nonderivatized, neutral OSs from human milk and infants' urine, enabling us to discriminate between the renal excretion of labeled, intact OSs originating from milk (HMO) and nonlabeled OSs of endogenous origin or resulting from HMO degradation. A dynamic insight into the metabolic fate of individual OS species in lactating women and their breastfed children over time is provided, and thereby indication is given for their functionality within infant's organism and the structures of active compounds.
Results
Directly before and up to 36 h after an oral application of 13 C-Gal to 10 lactating mothers, milk and their infants' urine were collected at each nursing, yielding >200 single milk and urine samples in total (Figure 1) . Some of the single urine samples could not be used for the analyses due to their insufficient volume or to fecal contamination in the diaper, causing discontinuations in the time course during the 36 h examination period. To adjust for the high variation of the urine volume and, therefore, analyte concentration prior to OS extraction, we determined creatinine concentration in each urine sample, since it is commonly used as reference parameter in clinical studies. The concentrations ranged from 30 to 250 mg creatinine/L of infants' urine. A urine volume corresponding to 0.1 mg creatinine was found to be optimal for OS extraction and MS analysis.
After solid-phase extraction (SPE), the OS profile of each individual sample was acquired by MALDI-TOF MS in positive ion mode (Figure 2 ). The OS species in milk and urine which could be detected in any of the 36 h samples of an individual are listed in Table I . OS profiles showed high interindividual variability, particularly in urine. For example, the molecular species with nominal mass 2044 for the lightest isotopomer [M + Na] + , referring to the glycan composition Hex 5 HexNAc 3 Fuc 4 , was only detected in the milk of women 3-9 and the urine of children 5 and 6. The mass-to-charge ratios (m/z), shown in the present work, represent nominal masses for sodiated glycans as detected in MALDI-TOF MS.
MALDI mass spectra provide mass isotopomer patterns of individual OS structure compositions (Figures 1 and 2 (Figure 2 ). The fA M+1 value of the samples collected prior to tracer application was regarded as baseline, except for woman 9 and infants 1, 8-10. Since no baseline Fig. 1 . Workflow of the in vivo isotope labeling experiment with mass isotopomer distribution evaluation via MALDI-TOF MS.
13 C-Gal was ingested by 10 lactating women and found to be incorporated into milk OSs. Labeled and unlabeled OSs were, in part, excreted in the urine of their breastfed infants. Enrichment of OSs with 13 C was followed over time by comparing the fractional abundances of the mass isotopomers at 0 < t < 36 h with those at baseline.
V Dotz et al. sample was available from these subjects, theoretical fA M+1 values, as calculated from the chemical formula of the OS and the natural isotope abundances of H, C, N and O, were applied to the statistical tests instead.
Time course of biosynthesis of milk OSs over 36 h For all 10 lactating women, an increase in fA M+1 could be observed in many OS species over time after 13 C-Gal ingestion. Some variability occurred in terms of the time pattern and the magnitude of tracer enrichment between both, subjects and single OS species. However, the overall time pattern of the fA M+1 values in Figure 3 is rather uniform with two or even three maxima within 36 h. Figure 3A shows data averaged from all 10 women, i.e., means of all fA M+1 determined in samples collected within a 4-h time interval. The coefficients of variance (CV) of the fractional abundances in larger OSs with m/z ≥ 1242 were ≤5% at most time points. Those OS species, which were most abundant in milk, i.e. isotopomers at m/z 731, 877, 1023, varied by 3−9%. The time pattern of fucosyllactose (m/z 512) showed highest inter-individual variations (3.43 ≤ CV ≤ 21.03%). An example of the time course of isotopomer enrichment in HMOs of a single donor is depicted in Figure 3C . The isotopomer abundances exhibit a consistently clear double-maximum time pattern in the milk of woman 3, even in case of fucosyllactose at m/z 512 ( Figure 3C ).
In order to confirm the significance of the isotopomer enrichment in milk and urine, we evaluated whether the MALDI-TOF MS fA M+1 values of the individual triplicate measurements from each sample at a certain time point differ significantly from baseline (Table II) . The individual data were grouped into 4-h intervals after statistical evaluation. The significant enrichment in the first half of the 36 h collection period persisted for ≤12 h in milk, starting directly at ≤4-8 h after tracer ingestion. Enrichment in the later period was more widely distributed over time and was significant in fewer OS species, indicating a third peak enrichment in women 2, 3 and 10. A slightly deviating time pattern was seen in milk samples of subject 5, in which the second maximum was more pronounced than the first (Table II) .
Time course of the urinary excretion of OSs in breastfed infants
As determined from fA M+1 in MALDI-TOF MS, the excretion of labeled OS in infants' urine was less pronounced than in milk and did not exhibit a uniform time pattern. Nevertheless, when compared with baseline, an increase of the fA M+1 values could be seen in many OS structures, with a maximum at 8-12 h after 13 C-Gal ingestion ( Figure 4 ). Accordingly, a significant increase of the isotopomer abundances was observed for the period between 4 and 16 h and at 20 h after 13 C-Gal ingestion (Table II) .
Method validation parameters
Sample preparation did not show any effects on the fA M+1 of the OS isotopomers, as indicated by percent relative standard deviation (%RSD) values not exceeding the variations originating from the MALDI-TOF MS instrument: The %RSD values Table I . Maltoheptaose was used as internal standard (m/z 1175).
Human milk oligosaccharides: Differences in metabolic fate from three different preparations of the same infant's urine and mother's milk, with fA M+1 values averaged from the analysis of three sample spots each, ranged from 0.85 (m/z 731) to 4.72 (m/z 1534) and 0.14 (m/z 1753) to 5.06 (m/z 1023), respectively. The spot-to-spot repeatability (intra-sample) of the fA M+1 values ranged from 1.11 (m/z 877) to 2.95 (m/z 1534) and from 0.66 (m/z 1388) to 5.27 (m/z 1607) %RSD, as measured from 10 different spots of one infant's urine and mother's milk OS preparation. The variation within the triplicate was monitored for each molecular species in each sample, as the signal intensity of the larger OSs, in particular, in the urine was highly subject-dependent. Most %RSD values were within the range measured for repeatability evaluation. However, a few OS species reached values of 10-15% (especially m/z 1242, 1534) in some samples. Those data have been marked in the diagrams (Figure 4 , Supplementary data) and excluded from the statistical tests. The same applies to low-abundant OS species having poor isotopomer patterns. Another uncertainty was the M + 1 isotopomer peak of sialyllactose, an acidic OS detectable in the positive ion mode, which overlapped with the M isotopomer of difucosyllactose at m/z 657 (see also Blank et al. 2011) . Therefore, we excluded difucosyllactose from further analyses. The resolution of the M + 1 OS isotopomers ranged from 6500 to >12,000. Structural identity of the OS was confirmed by fragmentation analysis (see also Blank et al. 2011) . Furthermore, MALDI-TOF MS runs with or without preceding SPE steps with blanks of pure water or dextran hydrolysate, or single HMO in water confirmed the absence of the OS species detected in the real samples, which are listed in Table I . Hence, an experimental cross-contamination of individual HMO samples could be excluded.
The internal standard detected at m/z 1176 did not exhibit significant variations in fA M+1 over time, as was also confirmed by statistical evaluation (Figures 3 and 4 ; Table II ). As an additional control for instrument-related effects on the measured fA M+1 values, we compared them with theoretical fA M+1 values calculated from the natural isotopic H, C, N and O abundances and the chemical formula of the OSs (see Figures 3B and 4 ).
Discussion
Our noninvasive study design comprised sample collection over 36 h with 10 time intervals, resulting in a finer time scale, but also in large numbers of samples with low sample volumes and low analyte concentrations in many cases. Thus, our approach, including automated SPE combined with rapid and sensitive MALDI-TOF MS analysis (see also Blank et al. 2011) , facilitates comprehensive in vivo metabolic studies with stable isotopes in infants, beyond a clinical setting.
To our knowledge, no comparable studies have been done so far to simultaneously trace the fate of >10 distinct glycans over time via two organisms, beginning from their biosynthesis in the mother up to their excretion in vivo in her infant. Several publications are available on studies applying 13 C tracers for elucidating the fate of single hexoses in infants and lactating women (Kalderon et al. 1989; Lapidot 1990; Sunehag et al. 2002) , having their focus on monosaccharides only.
Isotopomer abundances in mother-child pairs over time Isotopomer enrichment in milk OSs, as measured by MALDI-TOF MS, was observed in all 10 women a few hours after tracer ingestion, followed by a decline at 12-20 h ( Figure 3A) . This pattern was, except for fucosyllactose, homogeneous in all Table I ; m/z 1176 refers to the internal standard maltoheptaose.
Human milk oligosaccharides: Differences in metabolic fate The m/z of oligosaccharides (OS) are given for [M + 1 + Na] + ions, as analyzed by MALDI-TOF MS, which are significantly enriched when compared with baseline with P < 0.05 or with P < 0.01 (*), or P < 0.001 (#); n.s., not significant; -, no data. For OS structures see Table I . analyzed OSs, which indicates a successive incorporation of the 13 C tracer into distinct HMOs in the mammary gland after the single-dose application. Our previous IRMS data from whole milk and total neutral or acidic OS fractions showed a similar time pattern (Rudloff et al. 2006) . As has previously been suggested, the two-and three-maximum patterns over time in total enrichment of milk fractions might be explained by the secondary utilization of the tracer from the carbohydrate storage in other compartments (Rudloff et al. 2006) , such as glycogen, since the second maximum appears after night fast. Slight variations in the time pattern of tracer enrichment have been observed in more complex milk OSs with m/z ≥ 1753, equivalent with difucosylated octaoses and larger structures ( Figure 3A and C) . Since each molecular species in our data set represents a pool of various structural isomers, this is not surprising due to very likely differences in the kinetics of the biosynthesis of each isomer, which should be more pronounced in complex than in small OS species with less isomers.
The strong inter-individual and inter-structural variation in the tracer enrichment of the urinary OSs over time (Figure 4 ), in particular, if compared with a rather uniform pattern in milk, is an intriguing new finding. Moreover, it is surprising due to the fact that the overall MALDI-TOF MS profiles from urinary OSs resembled those from mother's milk (Figure 2) , which is in line with previous publications without stable isotope labeling (Chaturvedi et al. 2001; De Leoz et al. 2013) . Various explanations are possible for this striking deviation. First, despite the normalization to creatinine, the amount of labeled OSs in the urine varied, as time points for diaper change were not explicitly regulated. Secondly, gastrointestinal transit time may vary to a high extent, especially in infants (Sievers et al. 1993) . After 1 h of gastric transit (Vivatvakin et al. 2010) HMOs are thought to reach the proximal small intestine intact (Gnoth et al. 2000) . Then, various other individual factors, such as absorption, circulation and the excretion of the OSs, may have contributed to the variations in time. This can, in Human milk oligosaccharides: Differences in metabolic fate part, explain the delayed increase of isotopomer enrichment in several OS species in the urine of infants 2-5 and 10.
Regarding the metabolic fate of single OS species in each mother-child pair, we partly observed the appearance of the same 13 C-enriched OSs in infants' urine as in mothers' milk at a similar net time after tracer ingestion (Table II) . This indicates the excretion of intact HMOs in infants' urine after intestinal absorption, even for large and fucosylated OSs, such as the mono-, di-and trifucosylated hexaoses, with m/z 1242, 1388 and 1534, respectively. Strikingly, the 13 C-enrichment of those OSs in infants' urine, but not in milk, seems to be higher than those of the tetraoses, m/z 731, 877, 1023, in urine 4, 5, 6, 8 and 9 (Figure 4) . One may speculate that the larger OSs had been excreted in their intact form, originating from mother's milk, whereas tetraoses may, at least to a certain extent, reflect degradation products from larger HMOs, which had lost the 13 C tracer. Rudloff et al. (2006) reported that LNT was found to comprise the label in both Gal moieties. Unfortunately, further examination by means of fragmentation was not possible due to poor resolution of the isotopomers in the fragmentation mode. Furthermore, comparability between the OS species might be limited by accuracy considerations as discussed below.
An unexpected observation was that the excretion of labeled OSs in the urine of infants 1 and 9 was still significant at 28-36 h, although the enrichment in milk had been nonsignificant already about 16-20 h before. This finding suggests that OSs from milk may stay in infant's organism for several hours after absorption before being excreted via urine. Keeping in mind the various potential functions of HMOs, including both, intestinal as well as systemic effects (Bode 2012) , the question regarding retention time within the gut and child's organism seems crucial for a better understanding of their biological role in vivo. In this context, it is noteworthy that we also determined the isotopomer abundances in six fecal samples available from infant 1 between 8 and 32 h after 13 C-Gal application to the mother (Supplementary data). The time pattern of the fA M+1 varied remarkably between OS species. Interestingly, differences over time in the intestinal appearance of the same OS species in HMO-fed rats were recently reported by Jantscher- Krenn et al. (2013) . In vitro experiments on the transport of HMOs by intestinal Caco-2 cells indicated the possibility of re-secretion of some OS structures (Gnoth et al. 2001) , probably causing variations in their intestinal transit time. As soon as stable isotope-labeled HMO structures are available in future, studies applying singly labeled components to breastfed infants, preferably with collection of feces and urine for >36 h, should provide a more detailed insight into the metabolic fate of distinct structures. Since larger/smaller HMO may be degraded/modified to structures, which themselves resemble HMO structures again, stable isotope labeling techniques are the method of choice for the elucidation of their structurespecific metabolic fate in the infant.
In addition to the fA M+1 , we monitored the values for fA M+2 . The overall time patterns were similar to those of M+1. However, because of lower precision and higher variation in the fA M+2 of the internal standard, we excluded the M + 2 data from our calculations. The resulting uncertainty can be neglected here due to the low levels of precursor enrichment (Hellerstein and Neese 1999) .
Methodical considerations
Spot urine samples are known to vary in the concentration of the excreted substances, i.e., OSs as well as peptides and other interfering hydrophilic substances (Gowans and Fraser 1987) . Consequently, we standardized the urine volume for sample preparation to the creatinine concentration to assure comparability between the urine samples during SPE and MALDI-TOF MS analysis (see also Peelen et al. 1994) . Urinary creatinine excretion is known to be constant throughout the day and is therefore a common parameter for the excretion rate of various urinary analytes (Srivastava et al. 2007 ). In our samples, urinary creatinine concentration and, thus, presumably the analyte concentration varied by a factor of about 10.
The preparative and analytical procedure was validated based on the MALDI-TOF MS signal intensity and the fractional abundance precision and the resolution of the isotopomers. Supportively, we matched the measured baseline isotopomer abundances to their theoretical value and monitored the fA M+1 of the internal standard. In six women, we observed positive deviation of the baseline fA M+1 from theoretical values in milk OSs at m/z 512 and 876 by 8-26 and 6-12%RSD, respectively. This may be due to the chemical addition of hydrogen in the ion source, which is reported to increase with analyte concentration (Hellerstein and Neese 1999) . Congruously, these two molecular species count among the most abundant in the MALDI mass spectra from milk. Negative deviation from the expected theoretical values by 8% was observed in three women for the ions at m/z 1096, Hex 4 HexNAc 2 , an OS species which was low-abundant in most samples.
Conclusions MALDI-TOF MS has been proven as a suitable technique for the determination of OS isotopomer enrichment in human milk and infants' urine after in vivo labeling using a 13 C tracer. Following this approach, we were able to trace the metabolic fate of carbohydrates from the biosynthesis of individual OS species in the mammary gland to their excretion in the breastfed child over the course of time, and thus to discriminate between original HMOs and other nonlabeled OSs originating from possible endogenous sources or from HMO degradation. The direct comparison of OSs from milk and urine allowed us to detect remarkable differences in the time course and extent of tracer enrichment between single OS species in infants' urine. Former investigations from other groups did not suggest any modifications or notable utilization of HMOs after absorption, as non-labeled urinary OSs were analyzed, which reflected the specific profile found in mother's milk. Thus, we provide new indications for the role of HMOs within infant's organism, which has possibly been underestimated so far. Consequently, differentiated investigations in infants with single, stable isotope-labeled HMOs are still much-needed for a better understanding of the biology of HMOs. and 6-aza-2-thiothymine (ATT) were purchased from SigmaAldrich, Steinheim, Germany. Trifluoroacetic acid (TFA; ULC-MS grade) was purchased from LGC Standards, Wesel, Germany.
Materials and methods

Subjects and study design
Exclusively breastfeeding women (n = 10; 3-6 months postpartum) and their healthy, term infants participated in the study. The consumption of naturally 13 C-rich food was restricted. The study was approved by the ethics' committee of the University of Giessen. Written informed consent was obtained from all women. In the morning, mothers orally ingested a single dose Gal bolus consisting of 23 g Gal + 2 or 4 g 13 C-Gal, dissolved in 50 mL of drinking water (Rudloff et al. 2006 .
Sample collection
Milk (5-10 mL) had been obtained by manual expression before the Gal bolus was given (baseline value) and at the beginning of each nursing during the following 36 h (Figure 1 ). Infants' urine was collected in diapers consisting of cellulose, free of other adsorptive material (Procter & Gamble, Frankfurt, Germany) . In three infants, adhesive bags were used additionally for urine collection and were changed/emptied before each nursing and immediately frozen at −20°C, as well as the diapers. For urine extraction, diapers uncontaminated with feces were thawed and mechanically pressed. In previous experiments, it was verified that the urine collection via diapers and urine bags did not affect HMO analysis . The time course of isotopomer enrichment could not be analyzed in infant 7 due to an unclear documentation of urine collection time.
Isolation of OSs from human milk and infants' urine HMOs were prepared for extraction as described by Blank et al. (2011) . Fifty microliters of milk were centrifuged (14,000 × g) at room temperature for 20 min after the addition of 450 µL pure water. The aqueous phase was transferred into a 96-well plate. SPE with porous graphitic carbon (PGC) cartridges (HyperSep-96 Wells, 25 mg; Thermo Scientific, Bellefonte PA) was performed via a Hamilton Microlab Starlet liquid handling system (HamiltonRobotics, Reno, NV). Cartridges were equilibrated with 2 × 250 µL 40% ACN in water (v/v), followed by 2 × 250 µL 20% ACN in water (v/v), both containing 0.1% (v/ v) TFA. Prior to and after sample loading, the cartridges were washed with 5 × 500 µL 0.1% aqueous TFA and fully dried by vacuum. OSs were eluted with 400 µL aqueous 40/0.1% ACN/ TFA solution and dried overnight in a vacuum centrifuge (Blank et al. 2011) .
SPE of OSs from urine was performed manually using a Chromabond Vacuum manifold (Macherey-Nagel, Düren, Germany) with PGC cartridges (HyperSep Hypercarb 50 mg; Thermo Scientific, Bellefonte PA). After centrifugation (14,000 × g, 20 min, 4°C), 2-4 mL of diluted urine were loaded onto PGC cartridges, which were equilibrated as described for milk in the previous paragraph, but with 2 × 1 mL each. Following the washing with 5 × 1 mL 0.1% aqueous TFA, OSs were eluted in two fractions using 2 × 250 µL aqueous 40/0.1% ACN/TFA solution. For normalization of the amount of urinary constituents applied in the extraction procedure, creatinine concentration was determined using a colorimetric kit from R&D Systems (Parameter™, Minneapolis, MN).
OS analysis by MALDI-TOF MS
OSs were re-suspended in HPLC grade water and mixed with maltoheptaose as an isotopically nonenriched internal standard. The matrix, 35 mM ATT in 25 mM aqueous NH 4 HCO 3 , was pipetted in triplicate onto a MALDI AnchorChip™ 600 target plate (Bruker, Bremen, Germany) and mixed 1:1 with the OS sample. The matrix-sample spots were dried under cold air. Mass spectra were acquired using an Ultraflex I instrument (Bruker, Bremen, Germany), equipped with a nitrogen laser emitting at 337 nm. In the positive ion reflector mode, the voltage was set to 25 kV for acceleration, 26.3 kV for the reflector and 1.715 kV for the detector. Matrix ion deflection was off due to its impact on the detection of ions with m/z < 700. OS profiles were acquired in the mass range of m/z 360-3000. For calibration, dextran hydrolysate was used. Structural identification was performed by MALDI-TOF/TOF MS in the laserinduced dissociation mode, as described by Blank et al. (2011) . Data acquisition and analysis were done by the flexControl and flexAnalysis 3.0 software (Bruker, Bremen, Germany), respectively. The isotopomer peaks were detected by the Centroid algorithm. Fractional abundances for each OS isotopomer M + 1 were calculated as:
where I M is the intensity (height) of the mass isotopomer containing 1 H, 12 C, 14 N, 16 O and I M+1 is the intensity of its first isotopic peak (Figure 1) .
The theoretical fA M+1 were calculated by the Isotope Pattern Utility (flexAnalysis 3.0, Bruker, Bremen, Germany) based on the chemical formula of the OS and a natural abundance of the 13 C-isotope of 1.082%.
Statistical analysis
The fA M+1 of triplicate MALDI-MS measurements were processed in SPSS Statistics 20.0 (IBM, Ehningen, Germany) by one-way analysis of variance followed by Dunnett's one-tailed t-test, comparing the means of triplicates for each time point with the baseline sample. In case of unequal group variancesi.e. a significant Levene's test-Kruskal-Wallis H-test, followed by Dunnett's T3 post hoc test were run instead. The threshold for significance was set at P < 0.05.
Supplementary data
Supplementary data for this article is available online at http:// glycob.oxfordjournals.org/.
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